What is the ticagrelor?

ticagrelor is a medicine that prevents blood clots. He is a member of the class of medicines known as antiplatelets and is effective in preventing clots in large arteries, including aorta and lung blood vessels. This anticoagulant has been tested and proven to be more effective than many other drugs, but has not been approved for the use of the United States by the United States of Food and Drug Administration (FDA). The drug is available in the European Union. Different types of anti -handles affect the plates in different ways - inhibiting their creation, preventing aggregation, or preventing them from gluing with certain enzymes that help them cluster together. Ticagrelor is chemically different from other antiaplatelets. The effects of this drug are also reversible, unlike many other anti -concerns.Grel. Ticagrelor has been found to act faster than its competition. The death caused by blood -related problems such as stroke and heart attack was also lower. The experiment was double -blind with 18,624 patients.

Despite the positive results of the initial FDA study, the ticagrelor did not apply for use in the United States. In his own FDA study, he tested drugs using about 1,400 patients and found the same result. In the FDA study, fatal cardiovascular problem in the use of ticagrelor has been reported more often. Another reason FDA did not approve this medicine is that it causes more bleeding problems than clopidogrel, which was observed by both studies. This pose a risk to patients who needed to undergo surgery, although this problem could be eliminated if the drug was stopped 5 days before surgery.

It is not known why the results of these two studies have shown the opposite results, although the manufacturer of ticagrelor indicated that the dose of aspirin used along ticagrelor could have been improperly administered in American patients. Despite the poor performance of Ticagrelor in the FDA study voted advisory inýbor FDA 7 to 1 to approve drugs for use in the United States. In December 2010, however, the FDA refused. The manufacturer can perform another study to register for the FDA.